More than two years after its approval in Europe, PTC Therapeutics' gene therapy for rare genetic disorder AADC deficiency will soon be made available to patients in the US. The FDA has approved PTC's ...

In a potentially pivotal trial, PTC Therapeutics' experimental therapy for Huntington's disease (HD) met its primary endpoint, but questions about the data have raised doubts about the company's ...

Most Americans agree: This economy stinks. Practically every consumer sentiment survey and political poll points to that theme. People feel like their dollars aren’t stretching as far as before, and ...

PTC Industries (PTCIL)’s Q2FY26 EBITDA recovered to INR 257mn (+21% YoY), after a dismal Q1, as we believe TARC EBITDA losses would have reduced and ATL performance has improved. EBITDA margin, at ...

PTC is selling off its IoT businesses, Kepware and ThingWorx, in order to hone its focus on SaaS and AI, according to CEO Neil Barua, as the conglomerate announced a sale of the operations to asset ...

NHPC is unwilling to sell its stake in the power trading joint venture although it had, while shelving its buyout plan, said power trading was not its core business. New Delhi: After NHPC Ltd dropped ...

This software company's underlying growth rate is a lot stronger than the headline numbers indicate. ARR represents the "annualized value of our portfolio of active subscription software, SaaS, ...

If Wall Street had any doubts about Neil Barua filling the shoes of his predecessor Jim Heppelmann as chief executive at PTC, those doubts went out the (computer-designed) window last week. The Boston ...

PTC Inc. (NASDAQ:PTC) reported its Q3 2025 earnings, showcasing a strong performance that surpassed analyst expectations. The company achieved an earnings per share (EPS) of $1.64, significantly ...

Good afternoon, ladies and gentlemen. Thank you for standing by, and welcome to PTC's 2025 Third Quarter Conference Call. [Operator Instructions] Following the presentation, the conference will be ...